Drug
Efinopegdutide clinical trials
Also written JNJ-64565111 and MK-6024.
- studies test it
- 15
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
15 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 6 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 3 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 9
- Phase 2
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Merck Sharp & Dohme LLC (7) · Janssen Research & Development, LLC (7) · Janssen Pharmaceutical K.K. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses efinopegdutide is read from its arms, and is right about nine times in ten.
Testing it · 15
- A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)CompletedPhase 2Merck Sharp & Dohme LLCNCT06465186Written as Efinopegdutide
- Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)CompletedPhase 2Merck Sharp & Dohme LLCNCT06482112Written as Efinopegdutide
- A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)CompletedPhase 2Merck Sharp & Dohme LLCNCT05877547Written as Efinopegdutide
- A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT06052566Written as Efinopegdutide
- A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes MellitusCompletedPhase 1Janssen Research & Development, LLCNCT03235219Written as JNJ-64565111
- A Study to Evaluate JNJ-64565111 Pharmacokinetics and Safety in Adult Participants With Varying Degrees of Renal FunctionCompletedPhase 1Janssen Research & Development, LLCNCT03546205Written as JNJ-64565111
- Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64565111 in Type 2 Diabetes Mellitus (T2DM)TerminatedPhase 1Janssen Research & Development, LLCNCT02862431Written as JNJ-64565111
- A Study of Efinopegdutide in Healthy Obese Participants (MK-6024-015)CompletedPhase 1Merck Sharp & Dohme LLCNCT06701305Written as Efinopegdutide
- A Clinical Study of Efinopegdutide (MK-6024) in Healthy Chinese Volunteers (MK-6024-011)CompletedPhase 1Merck Sharp & Dohme LLCNCT06836037Written as Efinopegdutide
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian ParticipantsTerminatedPhase 1Janssen Pharmaceutical K.K.NCT03618160Written as JNJ-64565111
- A Study of Efinopegdutide (MK-6024) in Participants With Nonalcoholic Fatty Liver Disease (NAFLD) (MK-6024-001)CompletedPhase 2Merck Sharp & Dohme LLCNCT04944992Written as Efinopegdutide 20 mg/mL
- A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)CompletedPhase 1Janssen Research & Development, LLCNCT03606057Written as JNJ-64565111
- A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese ParticipantsCompletedPhase 2Janssen Research & Development, LLCNCT03486392Written as JNJ-64565111 Dose Level 1
- A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Severely Obese Participants With Type 2 Diabetes MellitusCompletedPhase 2Janssen Research & Development, LLCNCT03586830Written as JNJ-64565111 Dose Level 1
- A Study of JNJ-64565111 After Single Subcutaneous Administration at Different Injection Sites in Otherwise Healthy Overweight/Obese Adult Participants and a Study of JNJ-6456511 in Otherwise Healthy Obese Adult Participants After Multiple DoseCompletedPhase 1Janssen Research & Development, LLCNCT03586843Written as JNJ-64565111
Codes
What other systems call efinopegdutide · ClinicalTrials.gg INT016360
- UNII (FDA) DR6P1M58POEFINOPEGDUTIDEOne source FDA
- NCI Thesaurus C169932EfinopegdutideOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | DR6P1M58PO | EFINOPEGDUTIDE | One source FDA |
| NCI Thesaurus | C169932 | Efinopegdutide | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.